Yanren Peng1, Guojun Chen1, Hua Zheng1. 1. Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Abstract
OBJECTIVE: To investigate the triglyceride (TG)-lowering effects of PCSK9 inhibitor in patients with in different baseline triglyceride levels. METHODS: Between February, 2019 and March, 2020, a total of 59 patients were treated with PCSK9 inhibitor (Evolocumab) in 5 hospitals, including Nanfang Hospital, Guangdong Provincial People's Hospital, First Affiliated Hospital of Sun Yat-sen University, Foshan Nanhai District People's Hospital and Yulin First People's Hospital. According to baseline triglyceride levels, the patients were divided into normal TG group (< 1.70 mmol/L, n=24), mild hypertriglyceridemia group (1.70-2.29 mmol/L, n=11), moderate hypertriglyceridemia group (2.30-5.63 mmol/L, n=13), and severe hypertriglyceridemia group (≥5.64 mmol/L, n=11), and the changes in TG level after the treatment were compared among the 4 groups. RESULTS: In the groups with normal and mildly elevated baseline TG level, the patients did not show significant changes in TG levels after the treatment. In patients with moderately and severely elevated baseline TG levels, treatment with PCSK9 inhibitor significantly reduced their TG levels (P < 0.005). CONCLUSIONS: PCSK9 inhibitor has a significant TG-lowering effect in patients with moderate to severe hypertriglyceridemia but not in patients with only mildly elevated baseline TG level.
OBJECTIVE: To investigate the triglyceride (TG)-lowering effects of PCSK9 inhibitor in patients with in different baseline triglyceride levels. METHODS: Between February, 2019 and March, 2020, a total of 59 patients were treated with PCSK9 inhibitor (Evolocumab) in 5 hospitals, including Nanfang Hospital, Guangdong Provincial People's Hospital, First Affiliated Hospital of Sun Yat-sen University, Foshan Nanhai District People's Hospital and Yulin First People's Hospital. According to baseline triglyceride levels, the patients were divided into normal TG group (< 1.70 mmol/L, n=24), mild hypertriglyceridemia group (1.70-2.29 mmol/L, n=11), moderate hypertriglyceridemia group (2.30-5.63 mmol/L, n=13), and severe hypertriglyceridemia group (≥5.64 mmol/L, n=11), and the changes in TG level after the treatment were compared among the 4 groups. RESULTS: In the groups with normal and mildly elevated baseline TG level, the patients did not show significant changes in TG levels after the treatment. In patients with moderately and severely elevated baseline TG levels, treatment with PCSK9 inhibitor significantly reduced their TG levels (P < 0.005). CONCLUSIONS: PCSK9 inhibitor has a significant TG-lowering effect in patients with moderate to severe hypertriglyceridemia but not in patients with only mildly elevated baseline TG level.
Authors: Robert P Giugliano; Nihar R Desai; Payal Kohli; William J Rogers; Ransi Somaratne; Fannie Huang; Thomas Liu; Satishkumar Mohanavelu; Elaine B Hoffman; Shannon T McDonald; Timothy E Abrahamsen; Scott M Wasserman; Robert Scott; Marc S Sabatine Journal: Lancet Date: 2012-11-06 Impact factor: 79.321
Authors: Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein Journal: N Engl J Med Date: 2015-03-15 Impact factor: 91.245
Authors: Jacy Crosby; Gina M Peloso; Paul L Auer; David R Crosslin; Nathan O Stitziel; Leslie A Lange; Yingchang Lu; Zheng-zheng Tang; He Zhang; George Hindy; Nicholas Masca; Kathleen Stirrups; Stavroula Kanoni; Ron Do; Goo Jun; Youna Hu; Hyun Min Kang; Chenyi Xue; Anuj Goel; Martin Farrall; Stefano Duga; Pier Angelica Merlini; Rosanna Asselta; Domenico Girelli; Oliviero Olivieri; Nicola Martinelli; Wu Yin; Dermot Reilly; Elizabeth Speliotes; Caroline S Fox; Kristian Hveem; Oddgeir L Holmen; Majid Nikpay; Deborah N Farlow; Themistocles L Assimes; Nora Franceschini; Jennifer Robinson; Kari E North; Lisa W Martin; Mark DePristo; Namrata Gupta; Stefan A Escher; Jan-Håkan Jansson; Natalie Van Zuydam; Colin N A Palmer; Nicholas Wareham; Werner Koch; Thomas Meitinger; Annette Peters; Wolfgang Lieb; Raimund Erbel; Inke R Konig; Jochen Kruppa; Franziska Degenhardt; Omri Gottesman; Erwin P Bottinger; Christopher J O'Donnell; Bruce M Psaty; Christie M Ballantyne; Goncalo Abecasis; Jose M Ordovas; Olle Melander; Hugh Watkins; Marju Orho-Melander; Diego Ardissino; Ruth J F Loos; Ruth McPherson; Cristen J Willer; Jeanette Erdmann; Alistair S Hall; Nilesh J Samani; Panos Deloukas; Heribert Schunkert; James G Wilson; Charles Kooperberg; Stephen S Rich; Russell P Tracy; Dan-Yu Lin; David Altshuler; Stacey Gabriel; Deborah A Nickerson; Gail P Jarvik; L Adrienne Cupples; Alex P Reiner; Eric Boerwinkle; Sekar Kathiresan Journal: N Engl J Med Date: 2014-06-18 Impact factor: 91.245
Authors: Frederick J Raal; Narimon Honarpour; Dirk J Blom; G Kees Hovingh; Feng Xu; Rob Scott; Scott M Wasserman; Evan A Stein Journal: Lancet Date: 2014-10-01 Impact factor: 79.321